Trials / Completed
CompletedNCT01782495
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ombitasvir/paritaprevir/ritonavir and dasabuvir | Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet |
| DRUG | ombitasvir/paritaprevir/ritonavir | Tablet; ombitasvir coformulated with paritaprevir and ritonavir |
| DRUG | ribavirin | tablet |
Timeline
- Start date
- 2013-02-25
- Primary completion
- 2016-11-02
- Completion
- 2017-07-13
- First posted
- 2013-02-04
- Last updated
- 2017-11-07
- Results posted
- 2017-11-07
Source: ClinicalTrials.gov record NCT01782495. Inclusion in this directory is not an endorsement.